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Abstract 
Objective: Alterations in walking strategy and increased fall risk are recognised in 
people with Type 2 diabetes mellitus (T2DM), but the underlying basis and natural 
history are not clear. This study investigated alterations in walking strategy and 
dynamic sway (unsteadiness) in participants with impaired glucose tolerance (IGT) 
and T2DM in relation to the severity of neuropathy and vitamin D levels.  
Methods: 20 people with T2DM, 20 participants with IGT and 20 controls underwent 
gait analysis using a motion analysis system and force platforms, detailed assessment 
of neuropathy and serum 25 hydroxy-vitamin D (25(OH)D) levels.  
Results: Ankle strength (P=0.01) and power (P=0.003) during walking and walking 
speed (P=0.008) were preserved in participants with IGT but significantly lower in 
people with T2DM compared to controls. However, step width (P=0.005) and dynamic 
medio-lateral sway (P=0.007) were significantly higher and posterior maximal 
movement (P=0.000) was lower in participants with IGT, but preserved in T2DM 
compared to controls. Dynamic medio-lateral sway correlated with corneal nerve fiber 
length (P=0.001) and corneal nerve branch density (P=0.001), but not vibration 
perception threshold (P=0.19). 25(OH)D did not differ significantly between groups 
(P=0.10) and did not correlate with any walking variables or measures of dynamic 
sway. 
Conclusions: Early abnormalities in walking strategy and dynamic sway were evident 
in participants with IGT, whilst there was a reduction in ankle strength, power and 
walking speed in T2DM. Unsteadiness correlated with small, but not large fiber 
neuropathy and there was no relationship between vitamin D levels and walking 
variables.
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Novelty Statements 
• There are no studies comparing alterations in walking strategy and dynamic 
sway during walking in people with IGT and T2DM. 
• Distal muscle power and speed during walking were lower in people with 
T2DM compared to controls. 
• People with IGT but not T2DM had a significantly higher dynamic medio-
lateral sway during walking.  
•  Early alterations in dynamic sway during walking were associated with small 
but not large fiber neuropathy. 
• Vitamin D levels were not associated with alterations in walking strategy and 
dynamic sway in people with IGT or T2DM. 
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Introduction 
Walking impairment is perceived to be a late complication of diabetes, as it has been 
described primarily in patients with established neuropathy [1, 2]. However, a number 
of studies have shown walking impairment in people with diabetes before the onset of 
a large fiber neuropathy [3-6]. This suggests that either neuropathy may not be the 
only contributor to this abnormality, or that small rather than large fiber neuropathy 
may be a contributing factor.  
Peripheral neuropathy may result in biomechanical alterations in walking and balance, 
with an increased risk of falls  [1-3]. People with diabetes have reduced ankle and 
knee joint strength and power during walking as a result of distal muscular weakness 
[1]. Muscle weakness and alterations to muscle structure may lead to altered walking 
ability even in people without diabetic neuropathy [3]. Slower walking speed, shorter 
step length and wider step width have all been demonstrated, in people without 
diabetic neuropathy [4-6] and we have recently shown reduced lower limb strength 
and altered muscle structure in people with T2DM and minimal neuropathy [7]. 
Increased dynamic medio-lateral sway leading to unsteadiness has been reported in 
people with diabetic neuropathy [8]. Neuropathy can impair lower extremity function 
[9] and loss of vibration perception correlates with impaired dynamic medio-lateral 
sway in people with diabetes [8].  
Impaired glucose tolerance (IGT) may result in a small fiber neuropathy [10] and 
impaired standing balance and trunk position sense [11]. Furthermore, we have 
recently shown that distal lower limb muscle strength is reduced in participants with 
IGT, which could impact on gait and stability during normal walking [12]. 
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Muscle weakness, impairment of balance and an increased risk of falls have been 
associated with vitamin D deficiency during upright quiet standing and walking in 
healthy elderly participants [13]. Vitamin D deficiency can cause proximal muscle 
weakness, impaired dynamic sway during walking and an increased risk of falls [14] 
and of course reduced daily activity may lead to obesity and vitamin D deficiency [15]. 
The objectives of this study were: 
1. To investigate differences in walking characteristics and dynamic sway between 
people with IGT, T2DM and controls.  
2. To quantify the relationship between walking characteristics, neuropathy and 
vitamin D levels.  
 
Methods 
Participants  
20 people with Type 2 diabetes (8 with mild neuropathy and 12 without neuropathy) 
with a median and range of duration of diabetes 14 and 36 years, respectively; 20 
participants with IGT (10 with and 10 without neuropathy) and 20 participants without 
IGT or diabetes (controls) underwent assessment at the gait laboratory of the 
Manchester Metropolitan University. The study was approved by the UK National 
Health Service (NHS) ethics committee, local Research Ethics Committees at the 
University of Manchester and the Manchester Metropolitan University. Written 
informed consent was obtained from all participants.  
Assessment of Neuropathy 
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Symptoms of DPN were assessed using the Neuropathy Symptom Profile. 
Neurological deficits were evaluated using the simplified neuropathy disability score 
(NDS), comprised of assessing vibration perception threshold (VPT), pin-prick, 
temperature sensation and ankle reflexes. Diabetic sensorimotor polyneuropathy 
(DSPN) was defined according to the Toronto criteria [16]. Controls underwent 
assessment of VPT and NDS to confirm the absence of neuropathy. 
Small fibre neuropathy was evaluated by quantifying corneal nerve fiber density 
(CNFD); corneal nerve branch density (CNBD); corneal nerve fiber length (CNFL), 
corneal nerve fiber tortuosity (CNFT) and intraepidermal nerve fiber density (IENFD) 
in skin biopsies from the dorsum of the foot [17].  
Gait analysis 
Participants walked at their self-selected speed over a 10-m level ground walkway, 
stepping onto two of the three ground-embedded force platforms (Kistler, Winterthur, 
Switzerland), sampling at 1000Hz. Participant’s movement was assessed using a 10-
camera motion-capture system (Vicon, Oxford, UK), sampling at 100Hz. Using a full-
body modified Helen-Hayes marker set, 52 reflective markers were firmly fixed onto 
specific anatomical landmarks of the participant’s body (upper and lower body 
segments). Participants walked in standardised shoes appropriate for people with 
diabetes (MedSurg; Darco, Raisting, Germany) to control footwear condition and 
ensure that patients with diabetes walked with appropriate footwear. The mean data 
from four walking trials containing two force platform strikes with the left and two with 
the right foot was selected for analysis.   
Gait measurements 
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Ankle joint strength and power (peak values) during walking and temporal-spatial 
measurements (walking speed, step width and step length) were quantified for each 
participant using Visual 3D software (C-motion Inc., MD, USA) by combining the force 
and motion data.  
Dynamic Sway during Walking 
Dynamic sway is a term, which is used from this point on in the manuscript to define 
the separation distance between the body centre of mass (COM) and centre of 
pressure (COP) during walking in two planes: a frontal plane (medio-lateral dynamic 
sway) and a sagittal plane (anterior-posterior dynamic sway) (Figure 1). 
Statistical Analysis 
A one-way analysis of variance (ANOVA) with post-hoc Bonferroni was used to test 
the differences between the three independent study groups (T2DM, IGT and controls) 
for the measured variables. An independent samples Student’s t-test was used to 
assess differences between two groups for specific categories of variables: differences 
in walking and dynamic sway variables between people with and without neuropathy 
and with lower and higher values of vitamin D (25(OH)D < 25nmol/L vs > 25nmol/L). 
A Pearson’s correlation coefficient was used to assess the correlation between 
walking and dynamic sway variables. All the data are expressed as mean ± SD unless 
otherwise stated.  
The statistical power for the majority of walking and dynamic sway measurements in 
participants with IGT and T2DM was 0.80-1.00 (Table 2), which is very high 
considering an optimal recommendation is 0.8 [18]. We performed an a-priori power 
calculation based on ankle joint strength (torque) from a previous study [19]. The 
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power analysis indicated that we needed 14 subjects in each group to detect a 
difference of 22 Nm between groups (~20% difference between groups), with an alpha 
level of 0.05 and a beta level of 0.9 (i.e., power of 90%). To account for dropouts we 
recruited 20 participants into each group and also we adopted a more stringent alpha 
level (P<0.01).   
 
Results 
Clinical assessment  
20 healthy control participants (13 men and 7 women,  2 Asian and 18 European), 20 
participants with IGT (16 men and 4 women,  5 Asian and 15 European) and 20 
participants with T2DM (15 men and 5 women,  9 Asian & 11 European) were 
assessed. Participants were well matched for age and height, but body mass 
(P=0.006) and BMI (P=0.01) were significantly higher in participants with IGT 
compared to controls. HbA1c was significantly higher in participants with IGT and 
T2DM compared to controls. 25(OH)D did not differ significantly between groups 
(Table 1). 
Neuropathy assessments (Table 1) 
Vibration perception threshold (VPT) was significantly higher in participants with IGT 
(P=0.001) but not in T2DM (P=0.02) compared to controls. Neuropathy disability score 
(NDS) did not differ significantly between participants with IGT (P=0.02) and T2DM 
(P=0.04), but was higher compared to controls. Peroneal and sural nerve conduction 
velocity and amplitudes did not differ between groups. Corneal nerve fiber density 
(CNFD) was significantly lower in participants with IGT (P=0.004) and T2DM 
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(P=0.004) compared to controls. Corneal nerve branch density (CNBD) was 
significantly lower only in participants with IGT (P=0.002) compared to controls. 
Corneal nerve fiber length (CNFL), corneal nerve fiber tortuosity (CNFT) and 
intraepidermal nerve fiber density (IENFD) did not differ between groups. 
Peak ankle joint strength and power during walking (Table 2) 
During walking, peak ankle plantar flexion strength (P=0.01) and power (P=0.003) 
were significantly lower in people with T2DM compared to controls.  
Temporal-spatial gait measurements (Table 2) 
People with T2DM had a significantly slower walking speed (P=0.008) compared to 
controls. There was no difference in step length between either group, but there was 
a significantly greater step width (P=0.005) in participants with IGT compared to 
controls. 
Dynamic sway (Table 2) 
During walking, dynamic medio-lateral sway (P=0.007) was higher and posterior 
maximal movement (P=0.000) was lower in participants with IGT compared to 
controls.  
Peripheral neuropathy vs no peripheral neuropathy 
There were no significant differences in ankle plantar flexion strength (1.1±0.1 vs 
1.2±0.1 Nm/kg; P=0.87) and power (2.5±0.6 vs 2.6±0.7 W/kg; P=0.54), walking speed 
(1.3±0.2 vs 1.3±0.2 m/s; P=0.77), step width (13.0±2.8 vs 11.7±2.6 cm; P=0.11), step 
length (148.4±17.9 vs 140.1±19.9 cm; P=0.11) and dynamic medio-lateral sway 
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(14.9±8.0 vs 13.4±4.3 cm; P=0.46) in participants with (n=19) compared to participants 
without (n=41) peripheral neuropathy, respectively.  
Low (<25nmol/L) vs normal vitamin D (>25nmol/L) 
During walking, there was no significant difference in ankle plantar flexion strength 
(1.1±0.1 vs 1.2±0.1 Nm/kg; P=0.22) and power (2.3±0.5 vs 2.6±0.74 W/kg; P=0.12), 
walking speed (1.4±0.2 vs 1.3±0.2 m/s; P=0.13), step width (12.1±1.8 vs 12.1±2.8 cm; 
P=0.92) and dynamic medio-lateral sway (9.7±3.9 vs 8.4±3.8 cm; P=0.36), but step 
length (70.5±10.3 vs 75.1±5.9 cm; P=0.05) was reduced in participants with a 
25(OH)D level <25nmol/L vs. >25nmol/L. Dynamic medio-lateral sway was higher in 
people with T2DM (12.5±1.9 vs 8.1±2.4 cm; P=0.01) but not participants with IGT 
(8.2±4.9 vs 9.7±5.0 cm; P=0.62) comparing those with 25(OH)D levels <25nmol/L 
compared to >25nmol/L, respectively.   
Correlations 
There were low-to-moderate correlations between dynamic medio-lateral sway with 
CNFL (r=0.406; P=0.001) and CNBD (r=0.436; P=0.001), but no significant correlation 
with VPT (r=0.17; P=0.19). 
 
Discussion 
This is the first study to show an early alteration in the natural walking strategy and 
dynamic sway in participants with IGT, which is comparable to people with T2DM. This 
challenges the belief that balance impairment during walking only occurs in people 
with diabetes and advanced large fiber neuropathy [8]. Furthermore, we show that 
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small rather than large fiber abnormalities are more strongly associated with balance 
impairment. 
Whilst we confirm previous findings of a reduction in ankle joint strength and power 
during walking in people with T2DM [20, 21], we also show that participants with IGT 
display a reduction in ankle joint power during walking. These findings are supported 
by our recent data showing a significant weakness of the distal ankle plantar flexors in 
people with T2DM [7] and participants with IGT [12].  
It has previously been shown that people with diabetic neuropathy have a slower self-
selected walking speed, smaller step length and greater step width compared to 
controls [3, 20]. In the present study whilst walking velocity, stride length and step 
length were preserved; the step width was greater in participants with IGT, suggesting 
that this may be an early defect. Previously we have observed a greater step width in 
people with severe diabetic neuropathy compared to controls [8]. This was not found 
in people with diabetes in the present study as they had only mild neuropathy. 
However, the IGT group with an equivalent severity of neuropathy had adopted an 
increased step width, which may be attributed to the greater BMI in this group. Indeed, 
whilst a greater step width has been traditionally regarded as a way for people with 
diabetes to increase their base of support [22], we recently reported a positive 
correlation between step width and medio-lateral dynamic sway [8]. Thus increased 
step width may be an early sign of walking impairment in participants with IGT 
representing a more ‘cautious’ walking strategy commonly observed in people with 
diabetic neuropathy [5, 20].   
The lower ankle strength and power observed during walking in participants with IGT 
and diabetes may be one of the main underlying factors explaining the slower walking 
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speed, particularly ankle power which reflects aspects of both force and speed [2, 8, 
20, 23-25]. The slower walking speed observed in participants with IGT and T2DM 
may well be a compensatory strategy to lower the strength demands of walking as 
reported in previous studies in people with diabetes [26]. Furthermore, the reduced 
step length observed in participants with IGT and T2DM in the present study 
constitutes a ‘biomechanical strategy’ that helps to reduce the strength required from 
knee and ankle muscles by reducing the flexion (and therefore the required torque) of 
these joints.  
Reduced ankle strength and power during walking may play a role in unsteadiness, 
which can be quantified by measuring dynamic medio-lateral sway. Indeed, we have 
found that dynamic medio-lateral sway was already higher in participants with IGT 
during walking indicating greater unsteadiness, in agreement with our recent findings 
in people with diabetic neuropathy [8]. This is in line with previous findings of impaired 
postural sway during upright standing balance tests in participants with IGT [11]. In the 
present study we found a higher mean dynamic medio-lateral sway, in participants 
with IGT which means on average they demonstrated more side-to-side sway, 
whereas people with T2DM showed a greater range of dynamic medio-lateral sway, 
indicating that they periodically allowed greater side-to-side sway and more variability 
creating a more ‘dangerous’ situation in terms of the risk of falling for the T2DM group. 
Diabetic neuropathy may negatively impact on balance during walking [8, 25, 27] and 
indeed, a recent study has shown that people with diabetic neuropathy have a 
disturbance in postural sway during upright standing [28]. The presence of peripheral 
neuropathy may be a potential explanation for the increased medio-lateral sway 
observed in participants with IGT in the present study, however, our patients had 
evidence of minimal large fiber neuropathy. Traditionally it has been suggested that 
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quite marked impairment in sensation and proprioception is required to cause walking 
alterations [2, 20, 23, 25, 29], however, we now show significant alterations with 
minimal evidence of large fiber neuropathy.  
We have previously shown an association between loss of vibration perception and 
dynamic medio-lateral sway during walking in people with diabetes [8], however, in the 
present study we have found no correlation between VPT and medio-lateral sway, 
possibly because the majority of people with diabetes had very minimal large fiber 
neuropathy. However, a novel finding in the present study is the much stronger 
association between dynamic sway and small fiber neuropathy determined using 
corneal confocal microscopy. The mechanistic basis for the association between 
dynamic sway and small fiber pathology requires further study, especially as there was 
no association with IENFD in the foot. We have also shown that participants with IGT 
have smaller dynamic anterior-posterior sway, which reflects the shorter step length 
taken by participants with IGT, comparable to previous studies in people with diabetes 
[5, 8, 20]. The smaller posterior maximum anterior-posterior sway is likely explained 
by participants with IGT not allowing their body centre of mass to remain as far back 
compared to the controls and T2DM groups when transferring over to the leading leg 
during walking, this is likely because the joint moments (strength) associated with 
keeping the centre of mass any further back would be very high due to the flexed joints 
and high body mass of the IGT group.   
Severe vitamin D deficiency is related to postural instability during quiet standing and 
an increased risk of falls in elderly participants [30]. However, in the present study our 
participants did not have severe vitamin D deficiency, and we therefore compared low 
to relatively normal levels of vitamin D and found no relationship with walking strategy 
or unsteadiness. This finding is in agreement with our recent finding showing that 
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people with T2DM had a significantly reduced lower limb muscle strength, which was 
related to the severity of neuropathy but not to the level of vitamin D [7]. Although, in 
people with IGT we have recently shown a significant reduction in distal muscle 
strength, which was associated with increased intramuscular non-contractile tissue, 
small fiber neuropathy and vitamin D deficiency [12]. 
Vitamin D deficiency affects proximal more than distal muscles of the lower limb  [13, 
20]. The present study found that people with T2DM and low vitamin D had significantly 
higher dynamic medio-lateral sway compared to those with adequate levels of vitamin 
D, suggesting that vitamin D deficiency may have a role in balance impairment in 
T2DM. Previously healthy participants with severe vitamin D deficiency (<25nmol/L) 
have been shown to have decreased proximal muscle strength, increased postural 
sway during quiet standing and an increased risk of falls [31].  
We acknowledge the present study was undertaken with a small sample of subjects 
with a relative imbalance of ethnicities and did not include people with severe diabetic 
neuropathy or vitamin D deficiency, which may limit translation to the general 
population of subjects with IGT and T2DM. Furthermore, the assessment of walking 
strategy in a more challenging environment such as on stairs may have enhanced the 
clinical relevance of our findings.  
Conclusion 
Biomechanical changes to the natural walking strategy and balance control during 
walking occur in people with IGT and T2DM, and are related to small fiber neuropathy 
but not vitamin D deficiency. Larger, longitudinal studies are required to better 
understand the evolution and consequences of these abnormalities. 
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Table 1. Clinical  and neuropathy measures in controls and participants with 
IGT and T2DM. 
IGT: Impaired glucose tolerance; T2DM: Type 2 diabetes mellitus; BMI: Body mass 
index; IFCC: International Federation of Clinical Chemistry; DCC: Diabetes Control 
and Complications Trial; 25(OH)D: 25 hydroxy-vitamin D; NDS: Neuropathy disability 
score; VPT: Vibration perception threshold; SNVC: Sural sensory nerve conduction 
velocity; SNAP: Sural sensory nerve amplitude; PMNCV: Peroneal motor nerve 
conduction velocity; PMNAP: Peroneal motor nerve amplitude; CNFD: Corneal nerve 
fiber density; CNBD: Corneal nerve branch density; CNFL: Corneal nerve fiber length; 
Measurements Control 
n=20 
IGT 
n=20 
T2DM 
n=20 
P-value 
Age (years) 61.5±6.0 62.7±11.1 63.1±10.8 0.86 
Body mass (kg) 78.1±11.5 94.9±18.7(0.006) 82.6±18.2 0.006 
BMI (kg/m2) 27.2±3.8 31.5±5.5(0.01) 29.4±4.1 0.01 
HbA1c  
(mmol/mol) 
38.0±2.1 42.4±6.3(0.007) 53.8±10.6(0.000) 0.000 
HbA1c (%) 5.6±0.1 6.0±0.6(0.007) 7. 3±1.5(0.000) 0.000 
25(OH)D (nmol/L) 78.9±48.8 50.8±34.8 72.6±43.5 0.10 
NDS (0-10) 1.1±1.2 3.3±3.4(0.02) 3.1±2.5(0.04) 0.014 
VPT(Hz) 6.4±3.0 16.5±11.6(0.001) 13.7±8.6(0.02) 0.001 
SNCV (m/s) 48.6±4.5 45.8±13.6 47.4±4.4 0.58 
SNAP (μV) 13.7±7.2 14.5±14.8 11.6±5.6 0.62 
PMNCV (m/s) 46.6±4.7 41.4±10.7 42.2±7.05 0.08 
PMNAP (mV) 5.3±1.8 3.8±1.8 4.15±2.5 0.07 
CNFD (no/mm2) 35.9±5.1 27.6±8.2(0.004) 27.7±9.1(0.004) 0.001 
CNBD (no/mm2) 94.9±33.6 55.7±35.8(0.005) 93.9±41.5 0.002 
CNFL (mm/mm2) 26.7±3.8 21.8±6.5 23.1±8.6 0.06 
CNFT (TC) 16.4±2.7 18.6±6.5 20.2±4.3 0.05 
IENFD (no/mm) 7.7±2.0 6.7±3.4 7.6±5.4 0.70 
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CNFT: Corneal nerve fiber tortuosity; IENFD: Intraepidermal nerve fiber density. 
Significant differences between groups as a result of ANOVA (final column) and as a 
result of Bonferroni post-hoc (p value in superscript) compared to controls are 
indicated in bold.	Values are expressed as mean±SD. 
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Table 2. Walking measurements in controls and participants with IGT and 
T2DM. 
Measurements Controls IGT T2DM P-
value 
Statistic
al 
power 
(IGT) 
Statistic
al 
power 
(T2DM) 
Peak ankle 
strength (Nm/kg) 
1.2±0.2 1.1±0.2 1.1±0.2(0.01) 0.01 0.82 0.89 
Peak ankle 
power (W/kg) 
3.0±0.8 2.4±0.6 2.2±0.6(0.003) 0.002 0.99 1.00 
Temporal-
spatial gait 
measurements 
      
Walking speed 
(m/s) 
1.4±0.2 1.3±0.3 1.2±0.2(0.008) 0.008 0.65 1.00 
Step Length (cm) 74.7±6.8 70.4±12.8 69.0±8.2 0.15 0.62 0.96 
Step width (cm) 10.9±2.5 13.5±2.4(0.00
5) 
12.0±2.6 0.006 1.00 0.61 
Dynamic Sway 
(cm) 
      
Post. Max 28.0±2.8 17.7±5.5(0.00
0) 
25.7±2.8 0.000 1.00 0.98 
ML mean 5.0±2.5 8.1±3.7(0.007) 6.4±2.3 0.009 1.00 0.78 
IGT: Impaired glucose tolerance; T2DM: Type 2 diabetes mellitus; W: Watt; Post: 
Posterior; ML: Medio-lateral; Max: Maximum. Significant differences between groups 
as a result of ANOVA and as a result of Bonferroni post-hoc (p value in superscript) 
compared to controls are indicated in bold. Statistical power for each group is 
indicated.	Values are expressed as mean±SD. 
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Figure 1. Calculation of dynamic sway 
Figure legend 
Dynamic sway (S), defined as the separation of the body centre-of-mass (grey circle) 
and the centre-of-pressure (grey triangle). Dynamic sway is shown in the sagittal (left 
image) and frontal (right image) planes, illustrating the separation in the anterior-
posterior direction and medial-lateral directions, respectively. Also highlighted in the 
sagittal plane image is the resultant ground reaction force vector (grey arrow) and the 
ankle joint centre position (black cross): joint moments (strength) were calculated 
based on the relative position and magnitude of the ground reaction force from the 
joint centre, as well as taking into account the mass and acceleration of the relevant 
body segments. 
